<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382147</url>
  </required_header>
  <id_info>
    <org_study_id>2007-003103-12</org_study_id>
    <nct_id>NCT01382147</nct_id>
  </id_info>
  <brief_title>Evaluation of &quot;Dose-dense Therapy&quot; by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)</brief_title>
  <acronym>AMLCG 2008</acronym>
  <official_title>A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Wolfgang Hiddemann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kompetenznetz Leukämien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation weather early chemotherapy attempts for remission induction can improve the
      results of patients with Acute Myeloid Leukemia (AML), as compared to the standard group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2009</start_date>
  <completion_date type="Actual">July 5, 2017</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate, aiming at a 15% increase in the CR/PR rate by S-HAM induction versus conventional double induction [TAD - HAM for younger patients, HAM (- HAM) for elderly patients].</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">396</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>S-HAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-HAM (S-HAMescalated for younger patients and S-HAMbasis for elderly patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAD-HAM (younger) or HAM-HAM (elderly)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>is TAD-9 - HAM for younger patients (with 2 mandatory induction cycles) and HAM (- HAM) for the elderly patients with the second HAM cycle only applied in the case of inadequate blast clearance (&gt; 5%) in the day 16 bone marrow aspirate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C, Mitoxantrone, Daunorubicin, Thioguanin</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>S-HAM</arm_group_label>
    <arm_group_label>TAD-HAM (younger) or HAM-HAM (elderly)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed AML (except acute promyelocytic leukemia) according to
             the WHO classification including patients with secondary AML and AML after preceding
             hematologic disorders

          -  Age 18 years or older

          -  Informed consent. Before any study specific procedure including randomisation is done
             or before study medication is administered, the subject, or legally acceptable
             representative, must have given written informed consent for participation in the
             study.

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (APL)

          -  Previous or concurrent malignancies other than AML

          -  Previous treatment with colony-stimulating factors, interleukins or interferons

          -  Known hypersensitivity to Escherichia coli derived products (e.g. Filgrastim, HUMULIN®
             Insulin, L-Asparaginase, HUMATROPE® Growth Hormone, INTRON A®)

          -  Antibody-based or cell-based immunotherapies

          -  Respiratory insufficiency with pO2 &lt;60 mmHg

          -  Heart failure NYHA III° or IV°

          -  Elevated creatinine &gt;2.0 mg/dl

          -  Elevated bilirubin &gt;2.0 mg/dl

          -  Pregnancy or lactation

          -  Females without adequate contraception

          -  Known HIV and/or hepatitis C infection

          -  Severe neurologic or psychiatric disease

          -  Psychiatric, addictive, or any disorder, which compromises ability to give truly
             informed consent for participation in this study

          -  Concerns for subject's compliance with the protocol procedures

          -  Lack of willingness to record and circulate personal disease-related informations
             defined in the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Hiddemann, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of the University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vinzenz-Pallotti-Hospital, Innere Abteilung</name>
      <address>
        <city>Bergisch-Gladbach</city>
        <zip>51429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Hedwig Krankenhaus, Abteilung Innere Medizin</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukoelln, Innere Medizin - Haematologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch, Klinik für Haematologie, Onkologie und Tumorimmunologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Spandau, Klinik fuer Innere Medizin, Haematologie, Onkologie, Gastroenterologie und Palliativmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>13585</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld gGmbH, Klinik fuer Innere Medizin, Haematologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Bielefeld</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Krankenanstalt, Klinik fuer Haematologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Innere Medizin I</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bottrop, Klinik fuer Innere Medizin</name>
      <address>
        <city>Bottrop</city>
        <zip>46242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Johannes Hospital Dortmund, Klinik fuer Innere Medizin II</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Antonius-Hospital Eschweiler, Klinik fuer Haematologie und internistische Onkologie</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt / Oder GmbH, Medizinische Klinik I</name>
      <address>
        <city>Frankfurt / Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Josef-Hospital Gelsenkirchen-Horst, Klinik für Medizinische und Radiologische Onkologie, Hämatologie und Palliativmedizin</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Gütersloh, Medizinische Klinik II</name>
      <address>
        <city>Gütersloh</city>
        <zip>33332</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kath. Krankenhaus Hagen GmbH, Klinik fuer Haematologie und Onkologie</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Herford, Medizinische Klinik II</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Köln, Klinik I fuer Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Leverkusen gGmbH, Medizinische Klinik III</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Medizinische Klinik A</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Medizinische Klinik I, Haematologie / Onkologie</name>
      <address>
        <city>Luebbeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultaet Mannheim der Universitaet Heidelberg, III. Medizinische Klinik Haematologie und Internistische Onkologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl-von-Basedow-Klinikum Saalekreis GmbH, Medizinische Klinik II</name>
      <address>
        <city>Merseburg</city>
        <zip>06217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Maria Hilf GmbH, Krankenhaus St. Franziskus, Medizinische Klinik I</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen Medizinische Klinik und Polikklinik III</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Harlaching, Klinik für Onkologie und Haematologie</name>
      <address>
        <city>Muenchen</city>
        <zip>81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabrück, Klinik fuer Haematologie / Onkologie</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef Paderborn, Klinik fuer Haematologie / Onkologie</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder , Klinik fuer internistische Onkologie und Haematologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Marien-Krankenhaus Siegen gem. GmbH, Medizinische Klinik III</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftung Deutsche Klinik für Diagnostik GmbH, Zentrum fuer Knochenmark- und Stammzelltransplantation</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Idar-Oberstein GmbH, Innere Medizin I, Abteilung Haematologie / Onkologie</name>
      <address>
        <city>Îdar-Oberstein</city>
        <zip>55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Wolfgang Hiddemann</investigator_full_name>
    <investigator_title>Director of the Department of Medicine III</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

